IMPAKT 2017 is designed for breast cancer researchers and clinicians who have a specific interest in translational research, new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications in the clinical setting.
The programme can also benefit scientists, medical oncologists, breast surgeons, pathologists, imaging specialists, radiation oncologists, and other professionals involved in breast cancer research.
- New therapeutic strategies of endocrine dependent tumours
- Deciphering the immunotherapy landscape in breast cancer
- DNA repair and epigenetics in breast cancer
- Innovative clinical trial methodology to bring to the clinic faster biomarkers and technology
- Applying liquid biopsies to breast cancer clinical care
- The level of evidence for genomic alterations in breast cancer
ESMO-MORA: The IMPAKT Breast Cancer Conference programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. Learn more about ESMO-MORA recertification.
CME: The IMPAKT Breast Cancer Conference programme will also be submitted for accreditation to the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found online here.
The Symposium webcasts will include all the session of the official programme, where speaker permission is granted, and will be available on this website and OncologyPRO for ESMO members.